Use of Implanted Epidural Catheter for Opioid Delivery Appears Safe, Effective in Home Setting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK-An implanted epidural catheter can be a safe and effective means of providing analgesia in the home setting for patients with advanced cancer, Memorial Sloan-Kettering Cancer Center researchers found in a retrospective review.

NEW YORK-An implanted epidural catheter can be a safe and effectivemeans of providing analgesia in the home setting for patientswith advanced cancer, Memorial Sloan-Kettering Cancer Center researchersfound in a retrospective review.

Angela Racolin, RN, and her colleagues in the Anesthesiology PainManagement Group examined the charts of 40 cancer patients referredfor management of inadequate analgesia or intolerable opioid sideeffects.

These patients lived an average of 2.3 months after catheter implantation,with 85% dying at home, the majority with satisfactory pain reliefprovided by the epidural till the end.

"Most patients do deteriorate as their disease progresses,requiring multiple dosage changes," Ms. Racolin said in aninterview, "but we can usually do that with the home careagencies over the telephone, so patients can remain in their homes."

In her poster presentation, Ms. Racolin said that in this seriesof patients, there were no serious complications associated withthe epidural catheters or with the medications used-hydromorphone(Dilaudid), morphine, and fentanyl (Sublimaze).

One catheter had to be removed due to infection 7 months afterinsertion, and one catheter became dislodged 6 weeks after implantation.

Cost analysis showed an average charge of $200 to $600/day, dependingon the choice of analgesic drug and home care company. In thesepatients, with a life expectancy of 2.3 months, the total costper patient of epidural drug delivery with home nursing care rangedfrom $21,000 to $42,000.

"In our practice, there are patients who can't tolerate sufficientoral or parenteral medication to keep them comfortable, and theother options, such as regional nerve block or periodic epiduralbolus doses, may not be appropriate," she said. "Forthese patients, we view epidural delivery as a very viable, albeitexpensive, option."

Although less invasive methods are always tried first, "thecontroversy," she said, "is, how long do you put a patientthrough trials of different opioids before you go to an epidural?I don't think anyone has definitive guidelines about this, andit's going to be different for different people with differentkinds of disease."

Recent Videos
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Related Content